Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Khiron Life Sciences Corp.    KHRN   CA49374L3065

KHIRON LIFE SCIENCES CORP.

(KHRN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Khiron Life Sciences : Brazil Health Agency Authorizes Import of Khiron Medical Cannabis Product

share with twitter share with LinkedIn share with facebook
share via e-mail
02/07/2020 | 07:38am EDT
  • Authorization from the Brazilian Health Regulatory Agency (ANVISA) allows for Khiron medical cannabis product to be imported for use on an individual patient basis
  • Authorization follows December 2019 announcement by ANVISA allowing for a new class of medical cannabis-based product to be prescribed by doctors and sold through pharmacies, enabling patient safe and legal access
  • In Colombia, Company prepares for final authorization milestone allowing for domestic medical cannabis distribution
  • Brazil represents the largest addressable market in Latin America with an anticipated 3.4 million patient population and a potential USD $1.4 Billion network for medical cannabis (New Frontier Data)

TORONTO, Feb. 7, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that the Brazilian Health Regulatory Agency (ANVISA) has authorized for Khiron medical cannabis product to be imported into Brazil on an individual patient basis. This authorization will enable the Company to apply for a permit to export the product from Colombia. Commercialization in Brazil is also conditional on TSXV approval.

Khiron Life Sciences Corp. (CNW Group/Khiron Life Sciences Corp.)

"Within our LatAm strategy receipt of this authorization from ANVISA represents another regulatory milestone in bringing our medical cannabis products to the largest patient market in Latin America. With a continued focus on the health and wellbeing of patients in the region, we continue to grow our network in Brazil as we also work towards pending authorizations in Colombia and Peru." Comments Alvaro Torres, Khiron CEO and Director.

The announced regulatory framework, administered by the Brazilian Health Regulatory Agency (ANVISA), sets a comprehensive procedure for the manufacture and import of medical cannabis products and requirements for commercialization, prescription and dispensing. In the announcement, a new class of medical cannabis-based products will be prescribed by doctors and sold through pharmacies, enabling patient safe and legal access.

The medical cannabis market in Brazil is anticipated to grow to 3.4 million patients and a market of US$1.4 Billion within three years, including serving patients with chronic pain conditions (Source: New Frontier Data). Further, total requests for medical cannabis have tripled since 2015 (Source: ANVISA) and today, approximately 1,100 physicians are now prescribing medical cannabis to their patients.

About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox

Visit Khiron online at www.khiron.ca and on Instagram @khironlife

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/brazil-health-agency-authorizes-import-of-khiron-medical-cannabis-product-301000920.html

SOURCE Khiron Life Sciences Corp.

© Canada Newswire, source Canada Newswire English

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on KHIRON LIFE SCIENCES CORP.
04/03KHIRON LIFE SCIENCES : to Report 2019 Fiscal Year End Results and Provides Corpo..
AQ
03/31KHIRON LIFE SCIENCES : to Educate Physicians on Medical Cannabis Online with Lea..
AQ
03/30KHIRON LIFE SCIENCES : Meets Essential Patient Needs with Launch of Teleconsulta..
AQ
03/20KHIRON LIFE SCIENCES : IIROC Trading Resumption - KHRN
AQ
03/20KHIRON LIFE SCIENCES : Readies for First Medical Sales in Colombia and Provides ..
AQ
03/19KHIRON LIFE SCIENCES : IIROC Trading Halt - KHRN
AQ
03/05KHIRON LIFE SCIENCES : Poised to Enter Medical Cannabis Market in Peru
AQ
03/01KHIRON LIFE SCIENCES : is First Company Authorized to Extract High THC Medical C..
AQ
02/27KHIRON LIFE SCIENCES : Receives Approval of Normal Course Issuer Bid
AQ
02/26KHIRON LIFE SCIENCES : Granted Approval to Cultivate 9.3 Tons of THC Cannabis, R..
AQ
More news
Financials (CAD)
Sales 2019 9,30 M
EBIT 2019 -36,6 M
Net income 2019 -35,0 M
Finance 2019 28,0 M
Yield 2019 -
P/E ratio 2019 -1,73x
P/E ratio 2020 -5,20x
EV / Sales2019 3,51x
EV / Sales2020 2,54x
Capitalization 60,6 M
Chart KHIRON LIFE SCIENCES CORP.
Duration : Period :
Khiron Life Sciences Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 2,63  CAD
Last Close Price 0,52  CAD
Spread / Highest target 669%
Spread / Average Target 406%
Spread / Lowest Target 73,1%
EPS Revisions
Managers
NameTitle
Álvaro F. Torres Chairman & Chief Executive Officer
Chris Naprawa President
Manuel Buendia Vice President-Operations
Wendy Kaufman Chief Financial Officer
Maria Fernanda Arboleda Medical Director
Sector and Competitors
1st jan.Capitalization (M$)
KHIRON LIFE SCIENCES CORP.-50.94%48
CANOPY GROWTH CORPORATION-31.42%5 047
BEIJING TONGRENTANG CO., LTD0.36%4 909
DONG-E-E-JIAO CO.,LTD.1.91%2 355
CURALEAF HOLDINGS, INC.-37.16%2 061
CRONOS GROUP INC.-21.36%1 966